scispace - formally typeset
Search or ask a question
Journal ArticleDOI

Fermentation optimization for the production of lovastatin by Aspergillus terreus: use of response surface methodology

TL;DR: A Box-Behnken experimental design was used to investigate the effects of five factors (oxygen content in the gas phase, concentrations of C, N and P, and fermentation time) on the concentrations of biomass and lovastatin produced in batch cultures of Aspergillus terreus as discussed by the authors.
Abstract: A Box-Behnken experimental design was used to investigate the effects of five factors—ie oxygen content in the gas phase; concentrations of C, N and P; and fermentation time—on the concentrations of biomass and lovastatin produced in batch cultures of Aspergillus terreus. The values of the various factors in the experiment ranged widely, as follows: 20-80% (v/v) oxygen in the aeration gas; 8-48 g dm −3 C-concentration; 0.2-0.6 g dm −3 N-concentration; 0.5-2.5 g dm −3 phosphate-concentration; and 7-11 days fermentation time. No previous work has used statistical analysis in documenting the interactions between oxygen supply and nutrient concentrations in lovastatin production. The Box-Behnken design identified the oxygen content in the gas phase as the principal factor influencing the production of lovastatin. Both a limitation and excess of oxygen reduced lovastatin titers. A medium containing 48 g dm −3 C supplied as lactose, 0.46 g dm −3 N supplied as soybean meal, and 0.79 g dm −3 phosphate supplied as KH2PO4, was shown to support high titers (∼230 mg dm −3 )o f lovastatin in a7 -day fermentation in oxygen-rich conditions (80% v/v oxygen in the aeration gas). Under these conditions, the culture medium had excess carbon but limiting amounts of nitrogen. The optimized fermentation conditions raised the lovastatin titer by four-fold compared with the worst-case scenario within the range of factors investigated.  2004 Society of Chemical Industry

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI
TL;DR: In this paper , three strains of Aspergillus terreus were identified and designated AUMC 15760, aUMC 15762, and a UMC 15763 for the Assiut University Mycological Centre culture collection.
Abstract: Using the internal transcribed spacer (ITS) region for identification, three strains of Aspergillus terreus were identified and designated AUMC 15760, AUMC 15762, and AUMC 15763 for the Assiut University Mycological Centre culture collection. The ability of the three strains to manufacture lovastatin in solid-state fermentation (SSF) using wheat bran was assessed using gas chromatography-mass spectroscopy (GC-MS). The most potent strain was strain AUMC 15760, which was chosen to ferment nine types of lignocellulosic waste (barley bran, bean hay, date palm leaves, flax seeds, orange peels, rice straw, soy bean, sugarcane bagasse, and wheat bran), with sugarcane bagasse turning out to be the best substrate. After 10 days at pH 6.0 at 25 °C using sodium nitrate as the nitrogen source and a moisture content of 70%, the lovastatin output reached its maximum quantity (18.2 mg/g substrate). The medication was produced in lactone form as a white powder in its purest form using column chromatography. In-depth spectroscopy examination, including 1H, 13C-NMR, HR-ESI-MS, optical density, and LC-MS/MS analysis, as well as a comparison of the physical and spectroscopic data with published data, were used to identify the medication. At an IC50 of 69.536 ± 5.73 µM, the purified lovastatin displayed DPPH activity. Staphylococcus aureus and Staphylococcus epidermidis had MICs of 1.25 mg/mL, whereas Candida albicans and Candida glabrata had MICs of 2.5 mg/mL and 5.0 mg/mL, respectively, against pure lovastatin. As a component of sustainable development, this study offers a green (environmentally friendly) method for using sugarcane bagasse waste to produce valuable chemicals and value-added commodities.
Journal ArticleDOI
01 Jan 2008
TL;DR: The aim of this study was to validate method forin vitro analysis of dehidrolovastatin in plasm, which included studies of calibration curve and linearity, LLOQ and selectivity, accuracy, precision, recovery, and stability.
Abstract: Statins are antihyperlipidemic drugs for lowering LDL-cholesterol level in human blood. They were designed to inhibit HMG CoA reductase in the liver so that the enzyme will not catalyze the transformation of HMG CoA into early precursor of LDL-cholesterol. Dehydrolovastatin is a kind of statins whose structure is analogous to lovastatin (its starting material). The aim of this study was to validate method forin vitro analysis of dehidrolovastatin in plasm. The validation included studies of calibration curve and linearity, LLOQ and selectivity, accuracy, precision, recovery,and stability. Dehidrolovastatin was deteminated by Knauer r HPLC using UV 2500 detector, Kromasil r 100-5, C18, 250 mm, 4.6 mm i.d., column. Reversed phase was applied with the optimal condition such as mobile phase acetonitrile and phosphoricacid 0.1 % (75:25), the flow rate of 1.2 mL. minutesn -1, simvastatin as internal standard and wavelength 238 nm. Concentrations of sample ranged from 0.013 to0.200 ppm with correlation coefficient of the calibration curves 0,998 and lower limit of quantitation was 0.013 ppm. The results of validation studies fulfilled standard criteria.
References
More filters
Journal ArticleDOI
TL;DR: In this paper, a class of incomplete three level factorial designs useful for estimating the coefficients in a second degree graduating polynomial are described and the designs either meet, or approximately meet, the criterion of rotatability and for the most part can be orthogonally blocked.
Abstract: A class of incomplete three level factorial designs useful for estimating the coefficients in a second degree graduating polynomial are described. The designs either meet, or approximately meet, the criterion of rotatability and for the most part can be orthogonally blocked. A fully worked example is included.

3,194 citations

Journal ArticleDOI
TL;DR: It was shown that mevinolin was an orally active cholesterol-lowering agent in the dog and orally administered sodium mevinolinate was an active inhibitor of cholesterol synthesis in an acute assay.
Abstract: Mevinolin, a fungal metabolite, was isolated from cultures of Aspergillus terreus. The structure and absolute configuration of mevinolini and its open acid form, mevinolinic acid, were determined by a combination of physical techniques. Mevinolin was shown to be 1,2,6,7,8,8a-hexahydro-beta, delta-dihydroxy-2,6-dimethyl-8-(2-methyl-1-oxobutoxy)-1-naphthalene-hepatanoic acid delta-lactone. Mevinolin in the hydroxy-acid form, mevinolinic acid, is a potent competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase [mevalonate: NADP+ oxidoreductase (CoA-acylating), EC 1.1.1.34]; its Ki of 0.6 nM can be compared to 1.4 nM for the hydroxy acid form of the previously described related inhibitor, ML-236B (compactin, 6-demethylmevinolin). In the rat, orally administered sodium mevinolinate was an active inhibitor of cholesterol synthesis in an acute assay (50% inhibitory dose = 46 microgram/kg). Furthermore, it was shown that mevinolin was an orally active cholesterol-lowering agent in the dog. Treatment of dogs for 3 weeks with mevinolin at 8 mg/kg per day resulted in a 29.3 +/- 2.5% lowering of plasma cholesterol.

1,517 citations

Journal ArticleDOI
TL;DR: The experiments reported in this paper demonstrate that MG236A and ML-236B inhibit specifically 3-hydroxy-3-methylglutaryl (HMG)CoA reductase (EC 1 .I .1.34), the rate-limiting enzyme in cholesterol synthetic pathway, without affecting the rest of the enzymes involved in this pathway, and that the inhibition is competitive with respect to the substrate HMG-CoA.

699 citations

Journal ArticleDOI
TL;DR: This review deals with polyketides produced by the filamentous fungusMonascus which include: 1) a group of yellow, orange and red pigments, 2) agroup of antihypercholesterolemic agents including mevinolin and related compounds and 3) the newly discovered metabolite ankalactone.
Abstract: This review deals with polyketides produced by the filamentous fungusMonascus which include: 1) a group of yellow, orange and red pigments, 2) a group of antihypercholesterolemic agents including mevinolin and related compounds and 3) the newly discovered metabolite ankalactone. Biosynthesis, methods of production, isolation and biological activities of these secondary metabolites are discussed.

359 citations